Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02126969 · ClinicalTrials.gov registry record · Phase 2
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
A Phase 2 study, sponsored by Susanne Arnold.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02126969: Completed Phase 2 study, sponsored by Susanne Arnold.
NCT02126969 is a Phase 2 study that has completed, run by Susanne Arnold. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02126969, a Phase 2 study, has completed, sponsored by Susanne Arnold.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this effect differs from the cellular effect of higher, standard fractions of radiation used in traditional radiation treatment paradigms.
Primary Outcome
Primary site is defined as the original, or first site that the cancer developed in the body. In this study, primary sites within the head and neck included squamous cancers of the larynx, oral cavity, oropharynx, hypopharynx.Complete response rate in patients treated with 2 cycles of induction Docetaxel and Carboplatin with low dose fractionated radiation therapy (LDFRT) will be compared to those treated with chemotherapy alone. CRR was determined Per Response Evaluation Criteria In Solid Tumor
Interventions
- RADIATION Low dose fractionated radiation - 80cGy with chemotherapy
- DRUG Docetaxel and Carboplatin AUC 6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-10 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 2 |
What the finished NCT02126969 record still lists
NCT02126969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Low dose fractionated radiation - 80cGy with chemotherapy is the first listed.
NCT02126969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02126969 about?
NCT02126969 is a clinical study titled "A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN". The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this effect differs from the cellular effect of higher, standard fractions of radiation used in traditional radiation tr...
What is the current status of trial NCT02126969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-10. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT02126969?
The interventions under investigation include: Low dose fractionated radiation - 80cGy with chemotherapy (RADIATION), Docetaxel and Carboplatin AUC 6 (DRUG).
Who is sponsoring clinical trial NCT02126969?
This trial is sponsored by Susanne Arnold, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02126969's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia